Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors.

Abstract excerpt

BACKGROUND: This study aims to identify the genetic and clinical characteristics that affect the glycemic and weight loss responses to vildagliptin (Vilda) plus metformin (Met) among Egyptian obese type 2 diabetic (T2DM) patients. Furthermore, these responses were linked to homocysteine (Hcy) level as another cardiovascular risk factor. METHODS: One hundred twenty-six obese newly diagnosed T2DM Egyptian patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dipeptidyl Peptidase 4
• Share to Glucagon-Like Peptide-1 Receptor